Ventricular Tachycardia Ablation Guidance Includes Randomized Studies
This article was originally published in The Gray Sheet
Randomized clinical studies remain an option for sponsors seeking approval of ablation devices for the treatment of ventricular tachycardia (VT), FDA's Center for Devices and Radiological Health says in a recent guidance.
You may also be interested in...
Randomized controlled clinical trials of medical devices represent, in certain circumstances, the least burdensome route for sponsors to gain FDA approval, the agency maintains.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.